Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Innovating(IN) Shorter(S), All- Oral, Precised(P), Individualized(I) Treatment Regimen(RE) for Rifampicin Resistant Tuberculosis(INSPIRE-TB)

NCT05081401 is registered in ClinicalTrials.gov with Huashan Hospital as lead sponsor.

NCT NCT05081401
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05081401 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Innovating(IN) Shorter(S), All- Oral, Precised(P), Individualized(I) Treatment Regimen(RE) for Rifampicin Resistant Tuberculosis(INSPIRE-TB)
Lead sponsor
Huashan Hospital
Phase
Phase 3
Overall status
Recruiting
Start date
May 23, 2022
Completion date
December 1, 2027
Enrollment
1,050 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

multidrug resistant tuberculosis, pre-xdr-tb, rifampicin resistant tuberculosis